How many insider trades does FilingIQ track for CYDY?

FilingIQ tracks 291 Form 4 insider transactions for CYDY (CytoDyn Inc.), covering filings from Feb 6, 2015 onwards. 8 of those were filed in the last 90 days.

Are CYDY insiders net buyers or net sellers?

Across the full Form 4 history for CYDY, 18 transactions (6%) were open-market purchases and 11 (4%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does CYDY insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is CYDY in?

CytoDyn Inc. (CYDY) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $339.83M.

CYDY insider trading

OTC Markets OTCQB Healthcare

CytoDyn Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

291

Last 90 days

Buys / sells

6% / 4%

Market cap

$339.83M

About CytoDyn Inc.

CytoDyn Inc., a clinical-stage biotechnology company, develops treatments for multiple therapeutic indications. It is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19. The company's leronlimab is currently under phase 2 development for the treatment of micro-satellite stable colorectal cancer, and solid tumors in oncology, such as metastatic triple-negative breast cancer. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.

Company website: www.cytodyn.com

CYDY insider activity at a glance

FilingIQ has scored 291 insider transactions for CYDY since Feb 6, 2015. The most recent filing in our index is dated Mar 20, 2026.

Across the full history, 18 open-market purchases and 11 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on CYDY insider trades is 57.5/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live CYDY trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for CYDY?: FilingIQ tracks 291 Form 4 insider transactions for CYDY (CytoDyn Inc.), covering filings from Feb 6, 2015 onwards. 8 of those were filed in the last 90 days.
Are CYDY insiders net buyers or net sellers?: Across the full Form 4 history for CYDY, 18 transactions (6%) were open-market purchases and 11 (4%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does CYDY insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is CYDY in?: CytoDyn Inc. (CYDY) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $339.83M.

Methodology & sources

Every CYDY insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.